In continuing pattern, India revokes eye-drug patents

08/12/2013 | MedCityNews.com

India's patent appeals board revoked patents for Allergan's glaucoma medications Ganfort and Combigan. This rejection is the latest in a series of challenges to intellectual property claims by global drug firms that has included GlaxoSmithKline's breast-cancer drug Tykerb, Pfizer's cancer drug Sutent, Roche's hepatitis C drug Pegasys and Merck's asthma treatment. India's Supreme Court rejected Novartis' patent for the cancer treatment Glivec earlier this year.

View Full Article in:

MedCityNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX